Syndax Pharmaceuticals (DB:1T3) - Stock Price, News & Analysis

1T3 Stock Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.

About the company

1T3 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 74.7% below our estimate of its fair value

Revenue is forecast to grow 47.42% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Syndax Pharmaceuticals, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

MorphoSys

XTRA:MOR

€2.5b

Formycon

XTRA:FYB

€690.5m

Heidelberg Pharma

XTRA:HPHA

€141.7m

Price History & Performance

Summary of all time highs, changes and price drops for Syndax Pharmaceuticals
Historical stock prices
Current Share Price	US$19.20
52 Week High	US$22.00
52 Week Low	US$10.40
Beta	0.98
1 Month Change	-5.88%
3 Month Change	5.49%
1 Year Change	2.13%
3 Year Change	44.36%
5 Year Change	199.67%
Change since IPO	32.72%

Recent updates

Shareholder Returns

	1T3	DE Biotechs	DE Market
7D	-2.0%	-3.1%	1.8%
1Y	2.1%	-22.4%	2.2%

Return vs Industry: 1T3 exceeded the German Biotechs industry which returned -22.4% over the past year.

Return vs Market: 1T3 matched the German Market which returned 2.2% over the past year.

Price Volatility

Is 1T3's price volatile compared to industry and market?
1T3 volatility
1T3 Average Weekly Movement	6.7%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 1T3 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1T3's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2005	184	Michael Metzger	www.syndax.com

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat.

Syndax Pharmaceuticals, Inc. Fundamentals Summary

How do Syndax Pharmaceuticals's earnings and revenue compare to its market cap?
1T3 fundamental statistics
Market cap	€1.67b
Earnings (TTM)	-€195.63m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-8.4x

P/E Ratio

Is 1T3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1T3 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$209.36m
Earnings	-US$209.36m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.46
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 1T3 perform over the long term?

See historical performance and comparison

1T3 Stock Overview

Rewards

Risk Analysis

Syndax Pharmaceuticals, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:MOR

€2.5b

XTRA:FYB

€690.5m

XTRA:HPHA

€141.7m

Price History & Performance

Recent News & Updates

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

New minor risk - Profitability

Recent updates

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

New minor risk - Profitability

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Now 24% undervalued

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

New minor risk - Share price stability

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

First half 2022 earnings released

Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer

Investor sentiment improved over the past week

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.54 loss in 1Q 2021)

Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.46 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

First half 2021 earnings released: US$0.98 loss per share (vs US$0.97 loss in 1H 2020)

First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.56 loss in 1Q 2020)

Independent Chairman recently bought €164k worth of stock

Full year 2020 earnings released: US$1.87 loss per share (vs US$1.84 loss in FY 2019)

Revenue beats expectations

Syndax Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 08, 2021

Syndax Pharmaceuticals, Inc. Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD

New 90-day high: €19.50

Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting

New 90-day high: €16.00

Third quarter 2020 earnings released: US$0.46 loss per share

Revenue misses expectations

Syndax Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day high: €15.30